Toward Translation of Nanotechnology Cancer Interventions (TTNCIs)
TTNCI’s enable the translation of nanotechnology-based cancer interventions relying on nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. These awards are designed to mature experimental nanomedicines relying on "next-generation" nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.
Currently Active TTNCI Projects
- Mekhail Anwar/Bruce Cohen – UNIVERSITY OF CALIFORNIA, SAN FRANCISCO – Chip-Scale Intraoperative Optical Navigation with Immunotargeted Upconverting Nanoparticles
- Venessa Bellat –WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY – Customized Nanofibers with Preferential Lung-targeting Properties for Treating Metastatic Pulmonary Tumors
- Xiaohu Gao – UNIVERSITY OF WASHINGTON – Targeted RNA Delivery Using Ribonucleoprotein
- Cesar Castro/Hakho Lee – MASSACHUSETTS GENERAL HOSPITAL – High Throughput Nanoplasmonic Exosome Testing (NEXT) of Immunotherapies in Bladder Cancer
- Wen Jiang/Betty Kim – UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER –Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer Immunotherapy
- Alexander Kabanov – UNIVERSITY OF NORTH CAROLINA CHAPEL HILL – Toward Translation of Nanaoformulated Paclitaxel-Platinum Combination
- Raghuramann Kannan – UNIVERSITY OF MISSOURI-COLUMBIA – Towards Translation of MU-CN29: New Therapeutic Nanoparticle for DrugResistant NSCLC
- Glen Kwon – UNIVERSITY OF WISCONSIN-MADISON – Oligo(lactic acid)n-Prodrug Nanomedicines for Combination Therapy
- Chun Li – UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER –Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy
- Alexander Ljubimov – CEDARS-SINAI MEDICAL CENTER – Targeting Tumor Microenvironment by Nanoimmunodrugs for Glioma Treatment
- Julie Rhoades/Craig Duvall – VANDERBILT UNIVERSITY MEDICAL CENTER – Next Gen Targeted nanoparticles for Inhibiting Gli2 in Bone Metastatic Tumors
- Matthias Stephan – FRED HUTCHINSON CANCER RESEARCH CENTER – Developing Macrophage Reprogramming mRNA Nanocarriers for Initial Clinical Testing
- Shan Wang – STANFORD UNIVERSITY – Rapid and Affordable Magneto-Nanosensors for ctDNA-Guided Lung Cancer Management
- John Tanner Wilson – VANDERBILT UNIVERSITY – Toward Translation of an Immunotherapeutic Nanomedicine for Neuroblastoma
- Jin Xie/Zibo Li/William Kim – UNIVERSITY OF GEORGIA – Development of A Novel Biodegradable Inorganic Nanoparticle Therapeutic for Cancer
- Hu Yan/Kristoffer Valerie – MISSOURI UNIVERSITY OF SCIENCE & TECHNOLOGY– PEAMOtecan, A Novel Chronotheranostic Polymeric Drug for Brain Cancer with Potential Multi-Prong Drug Delivery Capability
- Yoon Yeo/Stephen Kron – PURDUE UNIVERSITY –Systemic Delivery of siRNA by Nanosac for Checkpoint Blockade Immunotherapy of Head and Neck Squamous Cell Cancer